← Eichor
Condition: Lewy Body Parkinson Disease Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Lewy Body Parkinson Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder
NA · 1 location(s) · Insel Gruppe AG, University Hospital Bern · NCT06629207Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder
NA · 1 location(s) · University of Minnesota · NCT06467461Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic On
Phase 2 · 2 location(s) · Fudan University · NCT05281003Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With idiOpathic anosMiA
Phase N/A · 2 location(s) · Danish Dementia Research Centre · NCT05740683Parkinson's Disease and Movement Disorders Clinical Database
Phase N/A · 1 location(s) · University of Pennsylvania · NCT04997642Natural History Study of Synucleinopathies
Phase N/A · 8 location(s) · NYU Langone Health · NCT01799915A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-0
Phase 2 · 38 location(s) · Merck Sharp & Dohme LLC · NCT06961006Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First
Phase 1/Phase 2 · 51 location(s) · Merck Sharp & Dohme LLC · NCT06469944Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
Phase N/A · 1 location(s) · Douglas Scharre · NCT03019757Parkinson's Disease Biomarkers in Nerve Cells in the Gut
Phase N/A · 1 location(s) · Weill Medical College of Cornell University · NCT0534740718F-mFBG Cardiac Uptake With Lewy Body Dementia
Phase 2 · 1 location(s) · Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radio · NCT07176286KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used W
Phase 1/Phase 2 · 46 location(s) · Merck Sharp & Dohme LLC · NCT04165070Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Phase 2 · 1 location(s) · Mark Garzotto, MD · NCT03753243Exergaming Revolution in Dementia
NA · 1 location(s) · Eastern Switzerland University of Applied Sciences · NCT06631742Prospective Multicenter Registry Study of Multiple System Atrophy in China
Phase N/A · 1 location(s) · Peking University First Hospital · NCT07644013Retinal Imaging in Neurodegenerative Disease
Phase N/A · 1 location(s) · Duke University · NCT03233646A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Al
Phase 3 · 261 location(s) · Merck Sharp & Dohme LLC · NCT06952504A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung C
Phase 3 · 225 location(s) · Merck Sharp & Dohme LLC · NCT06345729The Swedish BioFINDER 2 Study
NA · 2 location(s) · Skane University Hospital · NCT03174938A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 · 317 location(s) · Merck Sharp & Dohme LLC · NCT06966700Modifiable Variables in Parkinsonism (MVP)
Phase N/A · 1 location(s) · Bastyr University · NCT02194816Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patie
Phase 1 · 45 location(s) · BioNTech SE · NCT05142189Insulin Resistance in Multiple System Atrophy
NA · 1 location(s) · University Hospital, Bordeaux · NCT04250493Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05941338Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease
Phase N/A · 2 location(s) · Xuanwu Hospital, Beijing · NCT07498686A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung C
Phase 3 · 238 location(s) · Merck Sharp & Dohme LLC · NCT06623422DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Tre
Phase 3 · 250 location(s) · AstraZeneca · NCT06989112Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
NA · 1 location(s) · University Hospital, Bonn · NCT07324330Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypi
Phase N/A · 3 location(s) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT06846658Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Phase 3 · 21 location(s) · Taiho Pharmaceutical Co., Ltd. · NCT07710885
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.